Identification of Gene Variations Associated with Diabetic Neuropathy Using Bioinformatics Approach

Read full text Summarise with VIRAT
Authors: Siti Fatimah Sultan, Adisti Putri Novriyanti, Siti Rohmah, Lalu Muhammad Irham, Nanik Sulistyani, Muhammad Mar'uf
Cited by: 0
References: 40

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Diabetic neuropathy is the most common complication of diabetes, experienced by almost 90% of diabetic patients. Pain is one of the most common symptoms of diabetic neuropathy, but the pathophysiologic mechanism of pain is not clearly known. The hypothesis of hyperglycemia toxicity to the development of pain complications has been widely accepted worldwide, but there are still other hypotheses proposed. The basic concept in the management of painful diabetic neuropathy is to exclude other causes of peripheral neuropathic pain, improve glycemic control for prophylactic therapy, and use drugs to reduce pain. Variation data for diabetic neuropathy can be obtained from the Ensembl Genome Browser. Here, genes associated with 26 variants were selected according to Haploreg version 4.2. In addition, protein expression of missense gene variants was examined using the GTEx portal to determine two variants: rs55703767, which encodes the COL4A3 gene, and rs141560952, which encodes the DIS3L2 gene. According to data obtained from the Ensembl Genome Browser, the two most prevalent populations for SNP rs55703767, which is linked to the COL4A3 gene, are in Africa, while SNP rs141560952, which is linked to the DIS3L2 gene, is most prevalent in Africa, the Americas, East Asia, Europe, and South Asia.

Fields of Study & Subjects

Pain Mechanisms and Treatments Genetic Associations and Epidemiology Hereditary Neurological Disorders

Publication details

Journal / source
Borneo Journal of Pharmacy
Volume
9
Issue
1
Pages
48–48
Publication date
30 March 2026
Language
EN